Literature DB >> 32279346

Morphological anomalies of circulating blood cells in COVID-19.

Gina Zini1,2, Silvia Bellesi2, Francesco Ramundo1, Giuseppe d'Onofrio1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32279346      PMCID: PMC7262044          DOI: 10.1002/ajh.25824

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
Quantitative hematologic abnormalities have been described in the first patient studies of COVID‐19, the disease caused by the SARS‐CoV‐2 virus, currently responsible for a rapidly spreading pandemic, worldwide infection with high mortality rate. In severe cases, the disease progresses, through subsequent phases, from an upper respiratory tract infection with local and general flu‐like symptoms to a viral pneumonia and hyperinflammatory host reaction, which leads to acute respiratory distress and multi‐organ failure. The most common hematological findings include lymphocytopenia,1, 2, 3 neutrophilia,4, 5, 6 eosinopenia,7, 8 mild thrombocytopenia (35%) or, less frequently, thrombocytosis.2, 9 The presence of atypical, reactive lymphocytes has been only occasionally reported. In one recent report from California, a mild leuco‐erythroblastic picture was observed in the peripheral blood film. Italy has been, and still is severely hit by the epidemic. At Fondazione Policlinico A. Gemelli of Rome, a parallel COVID‐19 hospital has been created to provide assistance to patients from the region of Lazio and central Italy. We have had up to 249 patients with COVID‐19 admitted on March 25, 2020. After microscope observation of peripheral blood films from the first 40 cases at admission, when antiviral and anti‐inflammatory treatment was not yet administered, we have noted the presence of marked morphological abnormalities of the neutrophil lineage. Platelet morphology also showed peculiar and frequent anomalies, mainly with very large, usually hyperchromatic platelets with peripheral areas of different size, not rarely protruding in pseudopodia formations (Image 1L). This occurred both in patients with thrombocytosis (four cases with a count of 503‐629 × 109/L) and in those with thrombocytopenia (66‐93 × 109/L). Quantitative cell blood count (CBC) parameters were heterogeneous and overlapped with the majority of results from the literature.1, 2, 3, 4, 5, 6, 7, 8
IMAGE 1

Morphological anomalies in peripheral blood films from different COVID‐19 patients. A, Neutrophil granulocytes with bilobed and unsegmented, pseudo‐Pelgerlike nuclei. B, Neutrophil granulocytes with unsegmented nucleus with coarsely clumped chromatin; cytoplasm is hypergranular with basophilic, agranular areas. C, Unsegmented, hypergranular neutrophil with multiple vacuoles. D, Neutrophil granulocyte with marked cytoplasmic hypogranularity. E, Circulating small neutrophil myelocyte. F, Circulating dysplastic promyelocyte (scattered azurophil granules, absence of paranuclear Golgi zone). G, Immature circulating cell with blasts‐like reticular chromatin and rare thin azurophilic granules. H, Unsegmented granulocyte with hyperchromic nuclear chromatin and tightly condensed cytoplasm, likely pre‐apoptotic. I, Circulating apoptotic neutrophil. J, Apoptotic cell with blue cytoplasm, of possible lymphocyte origin. K, Large polyploid reactive lymphocyte with hyperbasophilic cytoplasm. L, Giant vacuolated platelets

Morphological anomalies in peripheral blood films from different COVID‐19 patients. A, Neutrophil granulocytes with bilobed and unsegmented, pseudo‐Pelgerlike nuclei. B, Neutrophil granulocytes with unsegmented nucleus with coarsely clumped chromatin; cytoplasm is hypergranular with basophilic, agranular areas. C, Unsegmented, hypergranular neutrophil with multiple vacuoles. D, Neutrophil granulocyte with marked cytoplasmic hypogranularity. E, Circulating small neutrophil myelocyte. F, Circulating dysplastic promyelocyte (scattered azurophil granules, absence of paranuclear Golgi zone). G, Immature circulating cell with blasts‐like reticular chromatin and rare thin azurophilic granules. H, Unsegmented granulocyte with hyperchromic nuclear chromatin and tightly condensed cytoplasm, likely pre‐apoptotic. I, Circulating apoptotic neutrophil. J, Apoptotic cell with blue cytoplasm, of possible lymphocyte origin. K, Large polyploid reactive lymphocyte with hyperbasophilic cytoplasm. L, Giant vacuolated platelets Neutrophil absolute counts were frequently increased in the first days after admission (>5 x109/L in 14/40 cases), before or just after the beginning of treatment, with a trend to decrease 1 week thereafter (1.48‐3.23 x109/Lin seven followed‐up cases). Their morphological abnormalities concerned both nuclear and cytoplasmic granulation (Image 1A‐D). In particular, we underline the presence of many, crowded, dark granulations in the cytoplasm (similar to “toxic” granules) and of peripheral light blue agranular areas. In a minority of cases, cytoplasmic hypogranularity was very frequent. Abnormalities of nuclear shape were striking, with increased frequency of band forms but also of dysmorphic cells with total absence of nuclear segmentation, consistent with pseudo‐Pelger morphology. Apoptotic cells were easily found in many peripheral blood films (Image 1H‐J). They appeared with liquefied nuclear chromatin and granulated or deep blue cytoplasm, suggesting possible derivation from different types of cells (ie, neutrophils and lymphocytes, respectively). Immature granulocytes, especially small myelocytes and metamyelocytes, were also frequently present in early phase cases (Image 1E), as recently described. More immature cells, sometimes showing immature nuclei and small azurophilic granules, were occasionally observed (Image 1F,G). Using the automated cytochemical reaction for myeloperoxidase, provided by the blood cell counter ADVIA 2120 (Siemens, Milan, Italy), in two of the 40 cases at diagnosis the neutrophil population showed a marked decrease of the peroxidase activity (Image 2), with myeloperoxidase index of −10.4 and −14.4, respectively (manufacturer’s normal range ± 10).
IMAGE 2

Partial myeloperoxidase (MPO) deficiency in a patient with dysmorphic neutrophils (same as Image 1A). The neutrophil population (purple signals) on the ADVIA 2120 scattergram is shifted to the left, partially invading the monocyte area (green signals), which determines a false increase of the monocyte percentage. Quantitative data: WBC 2.78 × 109/L, neutrophils 1.29 × 109/L, monocytes 0.89 × 109/L (falsely including a fraction of MPO‐deficient neutrophils), lymphocytes 0.41 × 109/L, large unstained cells (LUC) 0.19 × 109/L

Partial myeloperoxidase (MPO) deficiency in a patient with dysmorphic neutrophils (same as Image 1A). The neutrophil population (purple signals) on the ADVIA 2120 scattergram is shifted to the left, partially invading the monocyte area (green signals), which determines a false increase of the monocyte percentage. Quantitative data: WBC 2.78 × 109/L, neutrophils 1.29 × 109/L, monocytes 0.89 × 109/L (falsely including a fraction of MPO‐deficient neutrophils), lymphocytes 0.41 × 109/L, large unstained cells (LUC) 0.19 × 109/L In seven patients the peripheral blood film was re‐observed after 5 to 7 days of antiviral and anti‐inflammatory treatment. The above described neutrophil morphological changes had almost completely disappeared and the lymphocyte population showed wide morphological heterogeneity with large atypical lymphocytes (Image 1K), lymphoplasmacytoid cells and increased proportion of large granular lymphocytes. Treatment comprised antiviral, anti‐inflammatory and anti‐interleukin 6 products. In summary, it is our aim to point out that different cell morphological changes can be seen in the subsequent phases of COVID‐19. In particular, in the early phase of symptom aggravation, usually coinciding with hospital admission, a pronounced granulocytic reaction with immaturity, dysmorphism and apoptotic‐degenerative morphology was evident in peripheral blood. After several days of treatment, the hematologic picture tended to shift toward impressive lymphocyte activation, often with numerical increase, and heterogeneous morphological expression. These abnormalities mainly highlight the severe, transitory and reversible perturbation of myelopoiesis, especially in the form of accelerated and disordered granulopoiesis, in patients with COVID‐19 in severe symptomatic phase. According to recent updates, such quantitative and qualitative abnormalities can be related to the cytokine storm and hyperinflammation, which is a fundamental pathogenic factor in the evolution of COVID‐19 pneumonia. Possibly this is in the form of secondary hemophagocytic lymphohistiocytosis, leading to an often fatal multi‐organ failure.13, 14, 15 Our preliminary observation could therefore call for further studies of the involvement of myelopoiesis in the pathogenesis and evolution of COVID‐19.
  16 in total

1.  Papa Giovanni XXIII Bergamo Hospital at the time of the COVID-19 outbreak: Letter from the warfront….

Authors:  Sabrina Buoro; Fabiano Di Marco; Marco Rizzi; Fabrizio Fabretti; Ferdinando Luca Lorini; Simonetta Cesa; Stefano Fagiuoli
Journal:  Int J Lab Hematol       Date:  2020-06       Impact factor: 2.877

2.  Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.

Authors:  Chuan Qin; Luoqi Zhou; Ziwei Hu; Shuoqi Zhang; Sheng Yang; Yu Tao; Cuihong Xie; Ke Ma; Ke Shang; Wei Wang; Dai-Shi Tian
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

3.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Authors:  Qiurong Ruan; Kun Yang; Wenxia Wang; Lingyu Jiang; Jianxin Song
Journal:  Intensive Care Med       Date:  2020-03-03       Impact factor: 17.440

4.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

5.  Hematologic parameters in patients with COVID-19 infection.

Authors:  Bingwen Eugene Fan; Vanessa Cui Lian Chong; Stephrene Seok Wei Chan; Gek Hsiang Lim; Kian Guan Eric Lim; Guat Bee Tan; Sharavan Sadasiv Mucheli; Ponnudurai Kuperan; Kiat Hoe Ong
Journal:  Am J Hematol       Date:  2020-03-19       Impact factor: 10.047

6.  Clinical Characteristics of Refractory Coronavirus Disease 2019 in Wuhan, China.

Authors:  Pingzheng Mo; Yuanyuan Xing; Yu Xiao; Liping Deng; Qiu Zhao; Hongling Wang; Yong Xiong; Zhenshun Cheng; Shicheng Gao; Ke Liang; Mingqi Luo; Tielong Chen; Shihui Song; Zhiyong Ma; Xiaoping Chen; Ruiying Zheng; Qian Cao; Fan Wang; Yongxi Zhang
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

7.  Leukoerythroblastic reaction in a patient with COVID-19 infection.

Authors:  Anupam Mitra; Denis M Dwyre; Michael Schivo; George R Thompson; Stuart H Cohen; Nam Ku; John P Graff
Journal:  Am J Hematol       Date:  2020-04-06       Impact factor: 10.047

8.  Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series.

Authors:  G-Q Qian; N-B Yang; F Ding; A H Y Ma; Z-Y Wang; Y-F Shen; C-W Shi; X Lian; J-G Chu; L Chen; Z-Y Wang; D-W Ren; G-X Li; X-Q Chen; H-J Shen; X-M Chen
Journal:  QJM       Date:  2020-07-01

9.  Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia.

Authors:  Fan Wang; Jiayan Nie; Haizhou Wang; Qiu Zhao; Yong Xiong; Liping Deng; Shihui Song; Zhiyong Ma; Pingzheng Mo; Yongxi Zhang
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

10.  Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.

Authors:  Giuseppe Lippi; Mario Plebani; Brandon Michael Henry
Journal:  Clin Chim Acta       Date:  2020-03-13       Impact factor: 3.786

View more
  36 in total

1.  Overview of the Haematological Effects of COVID-19 Infection.

Authors:  T M Wiggill; E S Mayne; J L Vaughan; S Louw
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Spectrum of hematological changes in COVID-19.

Authors:  Smeeta Gajendra
Journal:  Am J Blood Res       Date:  2022-02-15

3.  Hematological Changes in the Second Wave of SARS-CoV-2 in North India.

Authors:  Akanksha Singh; Shailendra P Verma; Rashmi Kushwaha; Wahid Ali; Himanshu D Reddy; Uma S Singh
Journal:  Cureus       Date:  2022-03-25

4.  Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS-CoV-2 infection and long COVID.

Authors:  Matthew Plassmeyer; Oral Alpan; Michael J Corley; Thomas A Premeaux; Kimberleigh Lillard; Paige Coatney; Tina Vaziri; Suzan Michalsky; Alina P S Pang; Zaheer Bukhari; Stephen T Yeung; Teresa H Evering; Gail Naughton; Martin Latterich; Philip Mudd; Alfred Spada; Nicole Rindone; Denise Loizou; Søren Ulrik Sønder; Lishomwa C Ndhlovu; Raavi Gupta
Journal:  Allergy       Date:  2021-06-02       Impact factor: 14.710

5.  Laboratory divergences in concurrent diagnosis of acute myeloid leukemia relapse and COVID-19: A case report.

Authors:  Adrien Nizet; Jacques Foguenne; André Gothot; Françoise Tassin; Aurore Keutgens
Journal:  Int J Lab Hematol       Date:  2021-04-21       Impact factor: 3.450

6.  Morphological anomalies of circulating blood cells in COVID-19.

Authors:  Gina Zini; Silvia Bellesi; Francesco Ramundo; Giuseppe d'Onofrio
Journal:  Am J Hematol       Date:  2020-04-22       Impact factor: 10.047

7.  Clinical significance of blue-green neutrophil and monocyte cytoplasmic inclusions in SARS-CoV-2 positive critically ill patients.

Authors:  Miguel D Cantu; William S Towne; Foxwell N Emmons; Maria Mostyka; Alain Borczuk; Steven P Salvatore; He S Yang; Zhen Zhao; Ljiljana V Vasovic; Sabrina E Racine-Brzostek
Journal:  Br J Haematol       Date:  2020-06-13       Impact factor: 8.615

Review 8.  The clinical impact of COVID-19 epidemic in the hematologic setting.

Authors:  Carlo Finelli; Sarah Parisi
Journal:  Adv Biol Regul       Date:  2020-07-16

Review 9.  Haematological manifestations of COVID-19: From cytopenia to coagulopathy.

Authors:  Charles Agbuduwe; Supratik Basu
Journal:  Eur J Haematol       Date:  2020-08-31       Impact factor: 3.674

10.  Immune thrombocytopenia flare with mild COVID-19 infection in pregnancy: A case report.

Authors:  George Nesr; Catherine Garnett; Chris Bailey; Rincy Koshy; Siamak Arami
Journal:  Br J Haematol       Date:  2020-06-30       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.